Table 1 Characteristic of included studies
Author | Year | Location | Sample size | Title of research | Agea | Stage of disease | Reason of second-line therapy | Intervention | Control | Outcome | Follow-upb |
|---|---|---|---|---|---|---|---|---|---|---|---|
Fradet Y [18] supplementa | 2019 | Multicentre | 542 | KEYNOTE-045 | 65(26–86) | Advanced | Progression | Pembrolizumab | ICC | OS;PFS;ORR;AE | Open |
Rosenberg [19] | 2018 | Multicentre | 200 | Borealis-2 | 67(35–92) | Metastatic | Progression | Docetaxel plus Apatorsen | Docetaxel | OS;PFS;ORR;AE | Open |
Powles T [20] | 2018 | Multicentre | 931 | IMvigor211 | 67(31–88) | Advanced or metastatic | Progression | Atezolizumab | ICC | OS;PFS;ORR;AE | Open |
Petrylak DP [21] | 2017 | Multicentre | 530 | RANGE | 66(32–86) | Advanced or metastatic | Progression | Docetaxel plus ramucirumab | Docetaxel placebo | PFS;ORR;AE | Open |
Jones RJ [22] | 2017 | UK | 131 | NA | 69(61–77) | Advanced or metastatic | Progression | Pazopanib | Paclitaxel | OS;PFS;AE;QOLS | Open |
Bellmunt J [23] | 2017 | Multicentre | 70 | SECAVIN | 63(35–80) | Advanced | Failure | Cabazitaxel | Vinflunine | ORR;PFS;OS | Open |
Petrylak DP [24] | 2016 | Multicentre | 148 | NA | 66(29–85) | Advanced or metastatic | Progression | Docetaxel plus ramucirumab | Docetaxel plus icrucumab | PFS;OS;ORR;SAE | Open |
Santis MD [25] | 2016 | Multicentre | 69 | JASINT1 | 72(42–79) | Advanced | Unfit | Vinflunine;Gemcitabine | Vinflunine;Carboplatin | PFS;OS;SAE;ORR | 25.9 M(24.3–26.5) |
Noguchi M [26] | 2015 | Multicentre | 80 | NA | 65(46–84) | Advanced | Progression | PPV plus BSC | BSC | PFS;OS;SAE | 36 M |
Bellmunt J [27] | 2012 | Multicentre | 370 | NA | NA | Advanced | Failure | Vinflunine;BSC | BSC | OS;PFS;ORR;SAE | 21.5 M(16.7–25.3) |
Choueiri TK [28] | 2012 | Multicentre | 149 | NA | NA | Advanced or metastatic | Progression | Docetaxel;vandetanib | Docetaxel;placebo | PFS;OS;SAE;ORR | Open |
Santis MD [29] | 2011 | Multicentre | 238 | EORTC Study 30,986 | 71(34–87) | Advanced | Unfit | Gemcitabine;carboplatin | Methotrexate;carboplatin;vinblastine | OS;PFS;ORR;SAE | Open |
Culine Stephane [30] | 2011 | Frence | 44 | GETUG V01 | 76(48–86) | Advanced | Unfit | Gemcitabine | Gemcitabine;oxaliplatin | ORR;OS;SAE | Open |